Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
12 oct. 2017 17h00 HE
|
Zafgen, Inc.
BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected...
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
10 oct. 2017 07h00 HE
|
Zafgen, Inc.
BOSTON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected...
Zafgen to Present at the 2017 Ladenburg Thalmann Healthcare Conference
19 sept. 2017 16h05 HE
|
Zafgen, Inc.
BOSTON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
12 sept. 2017 16h05 HE
|
Zafgen, Inc.
BOSTON, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), today announced initiation of ZAF-1061-201, the Company’s Phase 2 clinical trial evaluating ZGN-1061 in patients with type 2...
Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
12 sept. 2017 08h00 HE
|
Zafgen, Inc.
- Data Demonstrate Dose-Dependent Beneficial Impact of ZGN-1061 on Glucose Tolerance, Body Weight and Cardiometabolic Markers- -Improvements in Glycemic Control Independent of Weight Loss- BOSTON,...
Zafgen Reports Second Quarter 2017 Financial Results
08 août 2017 16h05 HE
|
Zafgen, Inc.
-ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes- -Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year- -Ends Quarter with Cash,...
Zafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
02 août 2017 16h05 HE
|
Zafgen, Inc.
BOSTON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
01 août 2017 16h05 HE
|
Zafgen, Inc.
BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen to Present at the JMP Securities Life Sciences Conference
13 juin 2017 16h05 HE
|
Zafgen, Inc.
BOSTON, June 13, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic...
Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
10 juin 2017 13h00 HE
|
Zafgen, Inc.
-Successful Phase 1 Clinical Trial Garners Late-Breaking ADA Presentation and Supports Advancement to Phase 2 Development- -ZGN-1061 Treatment Improves Glycemic Control and Body Weight in Preclinical...